Results 131 to 140 of about 775,328 (297)

Minimal Residual Disease in Hematologic Disorders

Archives of Pathology & Laboratory Medicine, 1999
Abstract In almost no other area of medical oncology has the introduction of new drugs, combinations of chemotherapeutic agents, and novel biologic treatments caused such dramatic responses as it has in the treatment of malignant hematologic disorders.
S, Faderl, R, Kurzrock, Z, Estrov
openaire   +2 more sources

Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?

The Journal of Liquid Biopsy
Despite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due to occult micrometastasis.
Mara S. Serafini, Elisabetta Molteni, Eleonora Nicolò, Lorenzo Gerratana, Carolina Reduzzi, Massimo Cristofanilli   +5 more
doaj   +1 more source

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse [PDF]

, 2000
Válerie de Haas, Willemÿn B. Breunis, O. J. H. M. Verhagen, Henk van den Berg, C. Ellen van der Schoot   +4 more
openalex   +1 more source

Supplementary Table 4 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma [PDF]

, 2023
Janine Stutterheim, Fatima Ait Ichou, Emmy den Ouden, Rogier Versteeg, Huib N. Caron, Godelieve A.M. Tytgat, C. Ellen van der Schoot   +6 more
openalex   +1 more source

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia [PDF]

, 2019
Nicola Gökbuget, Hervé Dombret, Sebastian Giebel, Monika Brüggemann, Michael Doubek, Robin Foà, Dieter Hoelzer, Christopher Kim, Giovanni Martinelli, Е. Н. Паровичникова, Josep‐María Ribera, Marieke Schoonen, Catherine Tuglus, Gerhard Zugmaier, Renato Bassan   +14 more
openalex   +1 more source

Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia [PDF]

, 2014
Michael R. Savona
openalex   +1 more source

Methods to detect minimal residual disease

HemaSphere, 2018
Torsten Haferlach
doaj   +1 more source

Identifying leukemia‐associated immunophenotype‐based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance [PDF]

, 2019
Jing‐Ni Sui, Qiusheng Chen, Yun‐Xiang Zhang, Sheng Yan, Jing Wu, Junmin Li, Xiangqin Weng, Bing Chen   +7 more
openalex   +1 more source

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

, 2023
Christiane Pott, Vindi Jurinović, Judith Trotman, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiřı́ Mayer, Moya Young, Christian Schmidt, Andrea Knapp, Tina Nielsen, Helen B. Brown, Nathalie Spielewoy, Chris Harbron, Alessia Bottos, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann, Eva Hoster   +21 more
openalex   +1 more source

Targeting Minimal Residual Disease

Annual Review of Cancer Biology
Minimal residual disease (MRD) represents a significant challenge in the treatment of various cancers, acting as a precursor to relapse and therapeutic resistance. This review discusses the clinical background of MRD, exploring its role as a critical determinant in patient outcomes.
Yu-Ting Chou, Paul Allegakoen, Trever G. Bivona   +2 more
openaire   +1 more source